Skip to main content
. Author manuscript; available in PMC: 2016 Mar 3.
Published in final edited form as: Expert Opin Orphan Drugs. 2015 Apr 13;3(5):491–504. doi: 10.1517/21678707.2015.1025746

Figure 4.

Figure 4

a) Pathological abnormalities in the Neu1−/− hippocampus compared to control; in the Neu1−/− hippocampus APP starts to accumulate intracellularly as early as 1 month of age, as shown by immunohistochemistry analysis with anti-APP N-terminal antibody (brown; upper panel); amyloid deposits are observed in 5-month-old Neu1−/− brain stained positive for APP (N-terminal antibody; lower panel); b) Injection of an AAV containing human NEU1 and PPCA in the hippocampus of 4- (upper panel) and 6-month-old (lower panel) 5XFAD transgenic model (familial AD mouse model), showing reduction of the number of amyloid plaques compared with that seen in the 5XFAD animals injected only with carrier solution (plaques were identified by 4G8 immunostaining in brown). Adapted from Annunziata et al 2013 Nat Commun, with permission of Nature Publishing group.